Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis (NVS) announces new data on psoriatic arthritis drug, Cosentyx.

Novartis Reports Data on Cosentyx for Psoriatic Arthritis

Cisco Systems

Disney

Merck

Pfizer

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

According to the GuruFocus All-in-One Screener, the following stocks have outperformed the Standard & Poor's 500 Index over the last 12 months.

6 Large-Cap Stocks Outperforming the Benchmark

AbbVie

Bristol-Myers

Celgene

Vertex Pharmaceuticals

New blockbusters could be on the way for five drugmakers.

5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit

Novartis announced positive results from its phase 3 study using Kisqali to treat patients with HER+/HER2- advanced breast cancer.

Novartis Kisqali Might Have A Path Forward To Take On Pfizer's Ibrance

bluebird bio

bluebird bio gains regulatory approval in Europe for its gene therapy Zynteglo to treat patients with beta-thalassemia, which was the very first approval for it.

bluebird bio Breezes By For European Approval Of Its Gene Therapy Zynteglo

China Mobile Limited

HSBC Holdings

Coca-Cola

Taiwan Semiconductor Manufacturing

Wells Fargo

According to the GuruFocus All-in-One Screener, the following companies have high dividend yields but performed poorly over the last 12 months.

6 Stocks Paying High Dividend Yields

Abbott Labs

Johnson & Johnson

According to the GuruFocus All-In-One Screener, the following health care stocks are popular among gurus.

Five Health Care Stocks Gurus Are Buying

Biogen

Teva Pharmaceutical

The FDA and the EMA accept Celgene's (CELG) multiple sclerosis candidate, ozanimod, for review.

Celgene's Filing for Ozanimod Accepted for Review in US/EU

Novartis (NVS) appoints Marie-France Tschudin as head of the pharma unit. The company also provides a few pipeline updates.

Novartis Appoints New Pharma Unit Head, Gives Other Updates

Sanofi has appointed Novartis executive Paul Hudson to replace CEO Olivier Brandicourt who will retire in September.

Drugmaker Sanofi appoints Novartis' Hudson as CEO

Swiss pharmaceuticals giant Novartis named Marie-France Tschudin head of its main drugs business after its previous manager, Paul Hudson, was poised to take the CEO position at French drugmaker Sanofi.

Swiss drugmaker Novartis names new drug division head

Amgen

AstraZeneca

Roche Holding AG

Sanofi

The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.

Was ASCO Quieter for Big Drug/Biotech Stocks This Year?

Axovant Gene Therapies Ltd

The global market for drugs to treat neurodegeneration is expected to grow with a compound annual rate of 8% through 2022.

Novartis And Axovant Might Jointly Be Holding The Most Promising Neurodegeneration Drug In Development

Novartis (NVS) announces a number of data presentations at the ASCO 2019 annual meeting.

Novartis (NVS) Announces Various Data Presentations at ASCO

Gilead Sciences

Gilead (GILD) presents data from a phase I study on experimental CAR T cell therapy, KTE-X19, at ASCO and announces collaboration with Humanigen.

Gilead Presents Data on CAR T Cell Therapy Candidate at ASCO

Novartis' (NVS) investigational, once-daily, fixed dose combination asthma candidate, containing indacaterol acetate and mometasone furoate, meets goals.

Novartis (NVS) Reports Positive Phase III Data on Asthma Drug

Novartis' new gene therapy, Zolgensma, may be the most expensive drug ever, but there's much more to the story.

Bothered by the Price Tag of a $2.1 Million Drug? Read This Before Complaining Too Much

Novartis announced positive results from two phase 2 studies using QVM149 to treat patients with asthma.

Novartis's Positive Study For Treating Asthma Moves It One Step Closer To Market

Novartis gained FDA approval for Zolgensma to treat children under the age of 2 for spinal muscular atrophy, with treatment expected to cost $2.1 million.

Novartis Lands A Monumental Week, Gaining 2 FDA Approvals In One Day

Ionis Pharma

Novartis just got Zolgensma approved for spinal muscular astrophy, and it will compete with Spinraza.

Rent-A-Gene With Biogen's Spinraza, Or Buy-A-Gene With Novartis' Zolgensma

Novartis (NVS) obtains FDA approvals for a breast cancer drug and a gene therapy for pediatric patients.

Novartis Gets FDA Nod for Breast Cancer Drug & Gene Therapy

Getting end payers on board with a seven-figure price for Zolgensma won't be easy.

Can Novartis Convince Insurers a $2.1 Million Gene Therapy Is a Great Deal?

REGENXBIO

A $2.1 million price tag could make Zolgensma a blockbuster medicine for these companies.

Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and Regenxbio

Novartis AG said late Friday the U.S. Food and Drug Administration has approved one of its treatments for a type of advanced breast cancer afflicting patients carrying a gene mutation.

Novartis gets FDA nod for advanced breast-cancer treatment

U.S. regulators have approved the most expensive medicine ever, for a disorder that destroys a baby’s muscle control and kills nearly all of those with the most common variant of the disease within a couple years. The treatment is priced at $2.125 million.

FDA approves $2M medicine, most expensive ever

News for Novartis Stock (NVS)